Avantor Investor Day Presentation Deck

Avantor: A leading life science enterprise #1 / #2 GLOBAL PARTNER FOR LAB CONSUMABLES #1 / #2 GLOBAL MATERIALS PROVIDER FOR BIOPROCESSING AND BIOMATERIALS 2023E financials based on midpoint of FY 2023 guidance, as of Q3 2023 earnings call. Unlevered free cash flow excludes the impact of cash interest, net of tax impact. ~$7.0B 2023E REVENUE ~$650M 2023E FREE CASH FLOW ~$1.3B 1 2023E ADJUSTED EBITDA ~$850M 2023E UNLEVERED FREE CASH FLOW STRONG FOUNDATION Navantor™ 70

View entire presentation